FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Amicus Therapeutics Inc. (FOLD) is not a strong buy for a beginner, long-term investor at this time. The stock's potential sale to BioMarin at $14.50 per share caps its upside, and the financial performance shows significant declines in net income and EPS. While the technical indicators suggest a neutral to slightly bullish trend, there are no strong trading signals or positive catalysts to justify immediate investment.
The stock shows a mixed technical picture. The MACD is negative and contracting, indicating weak momentum. RSI is neutral at 72.555, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are close to the current price, suggesting limited upside potential.
The company is focused on rare disease therapies, with potential for significant sales growth in the long term. The stock is trading near the proposed acquisition price of $14.50, providing some stability.
Insider selling has increased significantly (110.68% over the last month). Analysts have downgraded the stock, and the proposed sale to BioMarin limits upside potential. Financial performance in the latest quarter shows sharp declines in net income (-357.19% YoY) and EPS (-400.00% YoY).
In Q3 2025, revenue increased by 19.46% YoY to $169.06M, but net income dropped by -357.19% YoY to $17.31M. EPS fell by -400% YoY to 0.06, and gross margin declined slightly to 87.38%.
Jefferies downgraded the stock to Hold from Buy with a reduced price target of $14.50, citing limited takeover interest. Citi initiated coverage with a Buy rating and a $17 price target, citing long-term growth potential in rare disease therapies.
